Sanofi Quick Ratio (SNY) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sanofi  (NASDAQ: SNY)

Sanofi's Quick Ratio

SNY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Sanofi's Cash & cash equivalent grew by 0.94 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Sanofi's Quick Ratio to 0.29, Quick Ratio remained below Sanofi average.

Within Major Pharmaceutical Preparations industry 201 other companies have achieved higher Quick Ratio than Sanofi in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1846, from total ranking in the third quarter 2025 at 2974.

Explain Quick Ratio?
How much Cash & cash equivalents SNY´s has?
What are SNY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SNY Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -2.8 % -2.8 % -2.8 % -2.8 % 103.26 %
Y / Y Cash & cash equivalent Change -0.43 % -1.36 % -1.36 % -1.36 % -10.28 %
Quick Ratio MRQ 0.29 0.28 0.28 0.28 0.28
SNY's Total Ranking # 1846 # 2974 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % -2.8 % 0 %
Seq. Cash & cash equivalent Change 0.94 % 0 % 0 % -1.36 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 202
Healthcare Sector # 414
Overall Market # 1846


Quick Ratio Statistics
High Average Low
0.88 0.52 0.28
(Dec 31 2022)   (Dec 31 2024)




Financial Statements
Sanofi's Current Liabilities $ 31,746 Millions Visit SNY's Balance sheet
Sanofi's Cash & cash equivalent $ 9,105 Millions Visit SNY's Balance sheet
Source of SNY's Sales Visit SNY's Sales by Geography


Cumulative Sanofi's Quick Ratio

SNY's Quick Ratio for the trailling 12 Months

SNY Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -2.8 % 12.14 % 32.17 % 60.42 % 103.26 %
Y / Y Cash & cash equivalent TTM Growth -1.13 % -3.78 % -6.06 % -8.23 % -10.28 %
Quick Ratio TTM 0.28 0.28 0.28 0.28 0.28
Total Ranking TTM # 3016 # # # # 2876
Seq. Current Liabilities TTM Growth -0.72 % -0.71 % -0.71 % -0.7 % 14.55 %
Seq. Cash & cash equivalent TTM Growth -0.11 % -0.34 % -0.34 % -0.34 % -2.79 %

Quick ratio ranking by company, industry and sector >> Back to SNY Financial Strength Comparisons >> Go to Compare SNY Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SNY's Current Liabilities to $31,746.40 millions, cumulative Quick Ratio to 0.28 below the SNY average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Quick Ratio than Sanofi. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3761 to 3821.

Explain Quick Ratio?
How much Cash & cash equivalents SNY´s has?
What are SNY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 489
Healthcare Sector # 1004
Within the Market # 1846


trailing twelve months Quick Ratio Statistics
High Average Low
0.7 0.4 0.26
(Dec 31 2020)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Harrow Inc   0.76 $ 72.927  Millions$ 96.302  Millions
Lifevantage Corp  0.74 $ 20.201  Millions$ 27.217  Millions
Supernus Pharmaceuticals inc   0.73 $ 128.448  Millions$ 177.074  Millions
Evolus Inc   0.71 $ 53.826  Millions$ 75.305  Millions
Geron Corporation  0.71 $ 79.440  Millions$ 111.542  Millions
Karyopharm Therapeutics Inc   0.69 $ 63.744  Millions$ 92.060  Millions
Eton Pharmaceuticals Inc   0.67 $ 25.942  Millions$ 38.490  Millions
Pharming Group N v   0.66 $ 145.305  Millions$ 221.690  Millions
Rein Therapeutics Inc   0.65 $ 3.215  Millions$ 4.916  Millions
Journey Medical Corp  0.64 $ 24.090  Millions$ 37.442  Millions
Ionis Pharmaceuticals Inc   0.64 $ 372.260  Millions$ 579.151  Millions
Pfizer Inc  0.63 $ 23,454.000  Millions$ 36,984.000  Millions
Lakewood-Amedex Biotherapeutics Inc.  0.62 $ 0.236  Millions$ 0.381  Millions
Jazz Pharmaceuticals Plc  0.62 $ 1,391.899  Millions$ 2,246.721  Millions
Ernexa Therapeutics Inc   0.61 $ 1.884  Millions$ 3.113  Millions
Enlivex Therapeutics Ltd  0.60 $ 5.441  Millions$ 9.021  Millions
Aurinia Pharmaceuticals Inc   0.59 $ 80.160  Millions$ 135.252  Millions
Promis Neurosciences inc   0.59 $ 6.150  Millions$ 10.441  Millions
Xencor Inc  0.58 $ 55.659  Millions$ 95.907  Millions
Ascendis Pharma A  0.58 $ 691.961  Millions$ 1,197.718  Millions
Earth Science Tech Inc   0.58 $ 1.811  Millions$ 3.146  Millions
Johnson and Johnson  0.57 $ 20,102.000  Millions$ 35,002.000  Millions
Ainos Inc   0.57 $ 0.417  Millions$ 0.729  Millions
Blue Water Vaccines Inc  0.57 $ 5.221  Millions$ 9.165  Millions
Esperion Therapeutics Inc   0.56 $ 167.852  Millions$ 300.810  Millions
Biofrontera Inc   0.54 $ 6.392  Millions$ 11.895  Millions
Bioxcel Therapeutics Inc   0.53 $ 28.415  Millions$ 53.926  Millions
Apollomics Inc   0.52 $ 3.276  Millions$ 6.326  Millions
Merck and Co Inc   0.51 $ 14,565.000  Millions$ 28,327.000  Millions
Jupiter Neurosciences Inc   0.51 $ 3.789  Millions$ 7.375  Millions

Date modified: 2026-06-24T10:07:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.